Pure Global Cannabis Inc. through its PureSinse Inc. announced that Phase 2 construction of the Company's Brampton campus, housing facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution, has been completed, coinciding with a recent on-site inspection for oils sales licensing by Health Canada. Phase 2 construction of the Company's Brampton campus is now complete and awaiting Health Canada approvals. The first phase, completed in 2018, includes vault storage built to Health Canada Level 9 standards, extraction, QA and microbiology labs as well as order processing, packaging, shipping and receiving, security IT and administrative areas. The company plans to begin cultivation and extraction in mid-summer subject to receiving Health Canada approvals, and expects its first harvest to be ready for sale in the fall of 2019. The 18,000 sq. ft. space will act as a hub for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. Phase 2 completion of the main site will also enable PureSinse to more effectively service patients interested in using extract-based products. This phase of completion provides an additional six flowering rooms of about 1,000 sq. ft. each, and includes a tissue culture lab, processing, drying and mothering rooms, as well as extraction areas. Coupled with R&D and tissue culture functions, this site will allow the Company to effectively cultivate close to three tons annually of cannabis and process extracts at six tons annual capacity. The third, and final phase, will expand the facility to 41,000 sq. ft. and include automated controlled growth cultivation systems that feature the company's proprietary vertical farming system. Total production capacity is expected to exceed 20,000 kg/year by the end of 2020. The vertical farming methodology will be validated on cannabis in phase two for full deployment in Phase 3. Phase 3 will also include a formulations lab, automated packaging, and scaled manufacturing for cannabidiol health and beauty and post-derivative products including edibles. Health Canada recently completed its on-site inspection for oils sales licensing. As Pure Global moves closer to obtaining oils sales licensing, it has expanded production capabilities to include in-house production of medicated topicals, creams, gels, balms, lotions, tinctures, sprays, vape pens, oils bottles, and gel capsules. This will boost the Company's product line capacity to meet the growing demand for post-derivative cannabis products which would be deployed throughout the Company's brand ecosystem as edibles and post-derivative products regulations are expected to come into being this fall.